216 related articles for article (PubMed ID: 23727512)
1. Differences in distribution and antimicrobial susceptibility of anaerobes isolated from complicated intra-abdominal infections versus diabetic foot infections.
Claros M; Citron DM; Goldstein EJ; Merriam CV; Tyrrell KL
Diagn Microbiol Infect Dis; 2013 Aug; 76(4):546-8. PubMed ID: 23727512
[TBL] [Abstract][Full Text] [Related]
2. In Vitro Activity of Ceftolozane-Tazobactam against Anaerobic Organisms Identified during the ASPECT-cIAI Study.
Armstrong ES; Farrell DJ; Palchak M; Steenbergen JN
Antimicrob Agents Chemother; 2016 Jan; 60(1):666-8. PubMed ID: 26552971
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy and correlation of clinical outcomes with in vitro susceptibility for anaerobic bacteria in patients with complicated intra-abdominal infections treated with moxifloxacin.
Goldstein EJ; Solomkin JS; Citron DM; Alder JD
Clin Infect Dis; 2011 Dec; 53(11):1074-80. PubMed ID: 21998288
[TBL] [Abstract][Full Text] [Related]
4. Bacteriology and antibiotic susceptibility of community-acquired intra-abdominal infection in children.
Lin WJ; Lo WT; Chu CC; Chu ML; Wang CC
J Microbiol Immunol Infect; 2006 Jun; 39(3):249-54. PubMed ID: 16783457
[TBL] [Abstract][Full Text] [Related]
5. Activity of ceftolozane-tazobactam against a broad spectrum of recent clinical anaerobic isolates.
Snydman DR; McDermott LA; Jacobus NV
Antimicrob Agents Chemother; 2014; 58(2):1218-23. PubMed ID: 24277025
[TBL] [Abstract][Full Text] [Related]
6. German multicentre survey of the antibiotic susceptibility of Bacteroides fragilis group and Prevotella species isolated from intra-abdominal infections: results from the PRISMA study.
Seifert H; Dalhoff A;
J Antimicrob Chemother; 2010 Nov; 65(11):2405-10. PubMed ID: 20851813
[TBL] [Abstract][Full Text] [Related]
7. In vitro activities of levofloxacin, gatifloxacin, moxifloxacin and garenoxacin against Bacteroides fragilis strains evaluated by kill kinetics.
Schaumann R; Janssen E; Funke M; Stîngu CS; Genzel GH; Janssen M; Rodloff AC
J Med Microbiol; 2013 Apr; 62(Pt 4):576-581. PubMed ID: 23319309
[TBL] [Abstract][Full Text] [Related]
8. Intra-abdominal anaerobic infections: bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agents.
Goldstein EJ
Clin Infect Dis; 2002 Sep; 35(Suppl 1):S106-11. PubMed ID: 12173118
[TBL] [Abstract][Full Text] [Related]
9. High rates of reduced susceptibility in the Bacteroides fragilis group isolated from blood cultures--the first national survey in Denmark.
Justesen US; Hansen F; Østergaard C; Schønheyder HC; Hansen DS; Lemming LE; Schumacher H; Heltberg O; Knudsen JD; Dzajic E; Arpi M; Hammerum AM
Int J Antimicrob Agents; 2013 Aug; 42(2):188-90. PubMed ID: 23773329
[No Abstract] [Full Text] [Related]
10. In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
Snydman DR; Jacobus NV; McDermott LA
Antimicrob Agents Chemother; 2008 Dec; 52(12):4492-6. PubMed ID: 18838581
[TBL] [Abstract][Full Text] [Related]
11. Carbapenem resistance in Bacteroides fragilis.
Ang L; Brenwald NP; Walker RM; Andrews J; Fraise A
J Antimicrob Chemother; 2007 May; 59(5):1042-4. PubMed ID: 17363423
[No Abstract] [Full Text] [Related]
12. The underappreciated in vitro activity of tedizolid against Bacteroides fragilis species, including strains resistant to metronidazole and carbapenems.
Goldstein EJ; Citron DM; Tyrrell KL; Leoncio ES; Merriam CV
Anaerobe; 2017 Feb; 43():1-3. PubMed ID: 27713022
[TBL] [Abstract][Full Text] [Related]
13. In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections.
Goldstein EJ; Citron DM; Warren YA; Tyrrell KL; Merriam CV; Fernandez HT
Antimicrob Agents Chemother; 2006 Aug; 50(8):2875-9. PubMed ID: 16870792
[TBL] [Abstract][Full Text] [Related]
14. Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents.
Citron DM; Goldstein EJ; Merriam CV; Lipsky BA; Abramson MA
J Clin Microbiol; 2007 Sep; 45(9):2819-28. PubMed ID: 17609322
[TBL] [Abstract][Full Text] [Related]
15. Bacteriology of diabetic foot.
El-Tahawy AT
Saudi Med J; 2000 Apr; 21(4):344-7. PubMed ID: 11533815
[TBL] [Abstract][Full Text] [Related]
16. Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007).
Snydman DR; Jacobus NV; McDermott LA; Golan Y; Hecht DW; Goldstein EJ; Harrell L; Jenkins S; Newton D; Pierson C; Rihs JD; Yu VL; Venezia R; Finegold SM; Rosenblatt JE; Gorbach SL
Clin Infect Dis; 2010 Jan; 50 Suppl 1():S26-33. PubMed ID: 20067390
[TBL] [Abstract][Full Text] [Related]
17. PCR-based detection of resistance genes in anaerobic bacteria isolated from intra-abdominal infections.
Tran CM; Tanaka K; Watanabe K
J Infect Chemother; 2013 Apr; 19(2):279-90. PubMed ID: 23338012
[TBL] [Abstract][Full Text] [Related]
18. [Bacteroides fragilis group in non-diarrheal human feces and its antimicrobial susceptibility].
Rodríguez E; Gamboa MM; Rodríguez C; Vargas P
Rev Esp Quimioter; 2006 Dec; 19(4):357-62. PubMed ID: 17235405
[TBL] [Abstract][Full Text] [Related]
19. Fatal sepsis caused by multidrug-resistant Bacteroides fragilis, harboring a cfiA gene and an upstream insertion sequence element, in Japan.
Nakamura I; Aoki K; Miura Y; Yamaguchi T; Matsumoto T
Anaerobe; 2017 Apr; 44():36-39. PubMed ID: 28108390
[TBL] [Abstract][Full Text] [Related]
20. [Diabetic foot infections. Prevalence and antibiotic sensitivity of the causative microorganisms].
Martínez-Gómez Dde A; Ramírez-Almagro C; Campillo-Soto A; Morales-Cuenca G; Pagán-Ortiz J; Aguayo-Albasini JL
Enferm Infecc Microbiol Clin; 2009 Jun; 27(6):317-21. PubMed ID: 19237227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
